Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global dyslipidemia therapeutics market is projected to experience substantial growth through 2028.
Statins to Remain the First-Line of Treatment for All Forms of Dyslipidemia
Fact.MR’s latest study on dyslipidemia therapeutics market offers in-depth analysis of growth drivers, restraints and current trends shaping the market dynamics. Its outlines various opportunities across leading segments in terms of type, drug class, distribution channel and region.
Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global dyslipidemia therapeutics market is projected to experience substantial growth through 2028. Growth is driven by rising prevalence of heart-related diseases, increasing spending on medicines, and growing health awareness among people.
Increasing prevalence of dyslipidemia has emerged as a serious health concern across the globe. Dyslipidemia is the imbalance of lipids such as cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and high-density lipoprotein (HDL).
Various studies have highlighted the role of dyslipidemia in triggering cardiovascular and other chronic heart diseases. To address this health issue, large number of dyslipidemia drugs are being consumed worldwide. This is, in turn, accelerating the growth in the market.
Moreover, various initiatives launched by government and other health organizations to spread awareness among people is positively impacting the market.
Consecutively, leading manufacturers are investing heavily in research and development activities for developing novel drugs. They are aiming at strengthening their supply and distribution channels. This is expected to bode well for the market.
If You Want To Know More About The Report @
https://www.factmr.com/connectus/sample?flag=S&rep_id=2928
Additionally, increasing penetration of online pharmacies across developing regions will continue to expand the dyslipidemia therapeutics market during the forecast period.
As per Fact.MR, statins will continue to dominate the dyslipidemia therapeutics market as a result of their higher effectiveness in lowering LDL levels. Clinical trials have confirmed the effectiveness of statins in reducing the risk of cardiovascular diseases while stabilizing the blood vessels lining.
Regionally, North America leads the dyslipidemia therapeutics market due to increasing prevalence of cardiovascular diseases, growing healthcare awareness and strong presence of key market players and rising trend of self-medication.
“Amid rising prevalence of dyslipidemia and other heart-related diseases, key players are employing various strategies such as co-promotion of dyslipidemia therapeutic drugs with local or regional players, aggressive marketing, new product launches, and high investments in research and development of novel drugs to dominate the market,” says a Fact.MR analyst
Key Takeaways from Dyslipidemia Therapeutics Market Survey
- North America is emerging as a key market for dyslipidemia on account of increasing cases of heart related diseases and strong presence of market players in the U.S.
- Europe is poised to exhibit strong growth due to surging geriatric population and continuous drug developments & approvals across the U.K. and Germany.
- Countries such as India and China are anticipated to grow at a healthy CAGR over the forecast period.
- In terms of type, low-density lipoproteins segment is likely to dominate the global dyslipidemia therapeutics market
- Hospital pharmacies segment is likely to retain its dominance in the dyslipidemia therapeutics market.
Key Drivers
- Rising trend of self-medication is positively impacting the growth in the market.
- Initiatives launched by governments to curb the burden of heart diseases will continue to boost the sales of dyslipidemia during the forecast period.
- New drug developments and approvals will create growth avenues within dyslipidemia market over the assessment period.
Key Restraints
- High cost of drug development and pre-clinical activities along with stringent approval regulations is hampering the growth of the market to some extent.
To learn more about Dyslipidemia Therapeutics Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=AE&rep_id=2928
Competitive Landscape
The global dyslipidemia therapeutics market remains consolidated, with leading players accounting for approximately 60% shares. They are also adopting various strategies such as mergers, partnerships, new drug developments and approvals to dominate the market.
- In December 2020, Novartis received European Commission (EC) approval of Leqvio (inclisiran) for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. Leqvio is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe.
- In September 2021, Amgen received the U.S. FDA approval of Repatha (evolocumab) for the treatment of pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
Some of the prominent players operating in the dyslipidemia therapeutics market profiled by Fact.MR are:
- Merck & Co.
- Pfizer
- Novelion Therapeutics
- Mylan
- Abbott Laboratories
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly
- AstraZeneca plc
- Amgen Inc.
- Kowa Pharmaceuticals America, Inc.
- Others
More Insights on the Global Dyslipidemia Therapeutics Sales Outlook
Fact.MR provides an unbiased analysis of dyslipidemia therapeutics market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for dyslipidemia therapeutics with a detailed segmentation on the basis of:
Type
- Low-density Lipoproteins (LDL)
- Triglycerides
Drug Class
- Statins
- Non-Statins
PCSK9 Inhibitors
Cholesterol Absorption Inhibitors
Bile Acid Resins or Sequestrants
Fibrate
Others
- Combination Drugs
Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Retail Stores
- Mail Order Pharmacies
Region
- North America
- Latin America
- Europe
- CIS & Russia
- Asia Pacific (Excluding China & Japan)
- China
- Japan
- Middle East and Africa
Key Questions Covered in the Dyslipidemia Therapeutics Market Outlook Report
- The report offers insight into dyslipidemia therapeutics demand outlook for 2018-2028
- The market study also highlights projected sales growth for dyslipidemia therapeutics market between 2018 and 2028
- Dyslipidemia therapeutics market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Dyslipidemia therapeutics market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain –
Familial Hypercholesterolemia Treatment Market Scope - Increased amounts of LDL (low-density lipoprotein) in the blood arteries induce familial hypercholesterolemia, a genetic disorder. Familial hypercholesterolemia is thought to put people at a higher risk of developing cardiac problems later in life. In the following decade, the market for familial hypercholesterolemia treatment is expected to rise due to rising diagnostic and treatment adoption rates. To keep up with demand, leading biopharmaceutical companies are focusing on extending their product line and raising adoption rates for familial hypercholesterolemia treatment.
Lipids Active Pharmaceutical Ingredient Market Insights - The market for lipids active pharmaceutical ingredients is predicted to develop due to the rising prevalence of cardiovascular diseases, neurological diseases, cancer, and other chronic diseases. Furthermore, the expansion of the lipids active pharmaceutical ingredient market has been fueled by increased demand for fast-acting and effective medications, as well as the development of modern drug production facilities.
About Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.
MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR